Related Experiment Video

Updated: Apr 25, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K

Paracrine network: another step in the complexity of resistance to EGFR blockade?

Ramon Salazar1, Gabriel Capellà2, Josep Tabernero3

  • 1Department of Medical Oncology and Translational Research Laboratory, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|August 21, 2014
PubMed

Insights

Limited KRAS-mutant clones in colorectal cancer may resist anti-EGFR therapy by secreting EGFR ligands. Further clinical studies are needed to confirm if this resistance mechanism is therapeutically targetable.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Colorectal cancer (CRC) treatment often involves anti-EGFR antibodies.
  • Resistance to anti-EGFR therapy is a significant clinical challenge.
  • KRAS mutations are common in CRC and associated with resistance.

Purpose of the Study:

  • To investigate the role of KRAS-mutant clones in mediating resistance to anti-EGFR antibodies in colorectal cancer.
  • To explore the potential paracrine mechanisms involved in this resistance.
  • To assess the clinical relevance and therapeutic potential of targeting this resistance pathway.

Main Methods:

  • Utilized colorectal cancer models.
  • Analyzed the secretion of EGFR ligands (amphiregulin and TGFα) by KRAS-mutant clones.
  • Evaluated the impact of ligand secretion on anti-EGFR antibody efficacy.

Main Results:

  • Identified increased secretion of amphiregulin and TGFα by limited KRAS-mutant clones.
  • These ligands are suggested to act in a paracrine manner, conferring resistance to anti-EGFR antibodies.
  • The biological basis for this resistance mechanism has been demonstrated in preclinical models.

Conclusions:

  • The findings suggest a novel paracrine resistance mechanism in anti-EGFR therapy for colorectal cancer.
  • Replication in clinical settings is crucial to validate these findings.
  • Further research is warranted to determine therapeutic exploitability.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

9.5K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
1.8K
Autocrine Signaling01:01

Autocrine Signaling

Autocrine signaling is one of the many signaling mechanisms that function inside multicellular organisms to carry out intercellular communication. In this type of signaling mechanism, the same cell that secretes an extracellular signaling molecule also expresses the receptors to bind and respond to that signaling molecule.
Autocrine Signaling in Macrophages
Under normal physiological conditions, autocrine signaling is essential for maintaining homeostasis. This process is well characterized in...
42.2K
Autocrine Signaling01:01

Autocrine Signaling

3.4K